nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—CYP2D6—Niacin—atherosclerosis	0.0824	0.3	CbGbCtD
Duloxetine—CYP2D6—Simvastatin—atherosclerosis	0.0652	0.237	CbGbCtD
Duloxetine—CYP2D6—Lovastatin—atherosclerosis	0.0638	0.232	CbGbCtD
Duloxetine—CYP2D6—Pravastatin—atherosclerosis	0.0638	0.232	CbGbCtD
Duloxetine—Cinacalcet—CASR—atherosclerosis	0.012	0.96	CrCbGaD
Duloxetine—HTR2A—arteriole—atherosclerosis	0.00414	0.254	CbGeAlD
Duloxetine—HTR2A—vein—atherosclerosis	0.00247	0.151	CbGeAlD
Duloxetine—HTR2A—hindlimb—atherosclerosis	0.00164	0.101	CbGeAlD
Duloxetine—NPY1R—adipose tissue—atherosclerosis	0.00151	0.0926	CbGeAlD
Duloxetine—HTR2A—appendage—atherosclerosis	0.00141	0.0863	CbGeAlD
Duloxetine—NPY1R—liver—atherosclerosis	0.00106	0.065	CbGeAlD
Duloxetine—HTR2A—artery—atherosclerosis	0.001	0.0617	CbGeAlD
Duloxetine—HTR2A—endothelium—atherosclerosis	0.000849	0.0521	CbGeAlD
Duloxetine—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000794	0.00161	CcSEcCtD
Duloxetine—Anaemia—Ezetimibe—atherosclerosis	0.000791	0.0016	CcSEcCtD
Duloxetine—Tinnitus—Pravastatin—atherosclerosis	0.000791	0.0016	CcSEcCtD
Duloxetine—Malaise—Lovastatin—atherosclerosis	0.000787	0.00159	CcSEcCtD
Duloxetine—Flushing—Pravastatin—atherosclerosis	0.000787	0.00159	CcSEcCtD
Duloxetine—Cardiac disorder—Pravastatin—atherosclerosis	0.000787	0.00159	CcSEcCtD
Duloxetine—Muscle spasms—Simvastatin—atherosclerosis	0.000785	0.00159	CcSEcCtD
Duloxetine—Vertigo—Lovastatin—atherosclerosis	0.000784	0.00159	CcSEcCtD
Duloxetine—HTR2A—blood vessel—atherosclerosis	0.000783	0.048	CbGeAlD
Duloxetine—Angioedema—Ezetimibe—atherosclerosis	0.000782	0.00158	CcSEcCtD
Duloxetine—Angiopathy—Niacin—atherosclerosis	0.000781	0.00158	CcSEcCtD
Duloxetine—Leukopenia—Lovastatin—atherosclerosis	0.000781	0.00158	CcSEcCtD
Duloxetine—Chills—Niacin—atherosclerosis	0.000773	0.00157	CcSEcCtD
Duloxetine—Malaise—Ezetimibe—atherosclerosis	0.000772	0.00156	CcSEcCtD
Duloxetine—Vision blurred—Simvastatin—atherosclerosis	0.000769	0.00156	CcSEcCtD
Duloxetine—Arrhythmia—Niacin—atherosclerosis	0.000769	0.00156	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000766	0.00155	CcSEcCtD
Duloxetine—Tremor—Simvastatin—atherosclerosis	0.000765	0.00155	CcSEcCtD
Duloxetine—Alopecia—Niacin—atherosclerosis	0.000761	0.00154	CcSEcCtD
Duloxetine—Chills—Pravastatin—atherosclerosis	0.000761	0.00154	CcSEcCtD
Duloxetine—Insomnia—Rosuvastatin—atherosclerosis	0.00076	0.00154	CcSEcCtD
Duloxetine—Ill-defined disorder—Simvastatin—atherosclerosis	0.000757	0.00153	CcSEcCtD
Duloxetine—Arrhythmia—Pravastatin—atherosclerosis	0.000757	0.00153	CcSEcCtD
Duloxetine—Palpitations—Ezetimibe—atherosclerosis	0.000757	0.00153	CcSEcCtD
Duloxetine—Paraesthesia—Rosuvastatin—atherosclerosis	0.000755	0.00153	CcSEcCtD
Duloxetine—Anaemia—Simvastatin—atherosclerosis	0.000755	0.00153	CcSEcCtD
Duloxetine—Malnutrition—Niacin—atherosclerosis	0.00075	0.00152	CcSEcCtD
Duloxetine—Erythema—Niacin—atherosclerosis	0.00075	0.00152	CcSEcCtD
Duloxetine—Alopecia—Pravastatin—atherosclerosis	0.000749	0.00152	CcSEcCtD
Duloxetine—Cough—Ezetimibe—atherosclerosis	0.000747	0.00151	CcSEcCtD
Duloxetine—Angioedema—Simvastatin—atherosclerosis	0.000746	0.00151	CcSEcCtD
Duloxetine—Chest pain—Lovastatin—atherosclerosis	0.000743	0.00151	CcSEcCtD
Duloxetine—Arthralgia—Lovastatin—atherosclerosis	0.000743	0.00151	CcSEcCtD
Duloxetine—Myalgia—Lovastatin—atherosclerosis	0.000743	0.00151	CcSEcCtD
Duloxetine—Anxiety—Lovastatin—atherosclerosis	0.00074	0.0015	CcSEcCtD
Duloxetine—Dyspepsia—Rosuvastatin—atherosclerosis	0.00074	0.0015	CcSEcCtD
Duloxetine—Hypertension—Ezetimibe—atherosclerosis	0.000739	0.0015	CcSEcCtD
Duloxetine—Flatulence—Niacin—atherosclerosis	0.000739	0.0015	CcSEcCtD
Duloxetine—Malaise—Simvastatin—atherosclerosis	0.000736	0.00149	CcSEcCtD
Duloxetine—Tension—Niacin—atherosclerosis	0.000736	0.00149	CcSEcCtD
Duloxetine—Discomfort—Lovastatin—atherosclerosis	0.000734	0.00149	CcSEcCtD
Duloxetine—Vertigo—Simvastatin—atherosclerosis	0.000733	0.00149	CcSEcCtD
Duloxetine—Leukopenia—Simvastatin—atherosclerosis	0.000731	0.00148	CcSEcCtD
Duloxetine—Myalgia—Ezetimibe—atherosclerosis	0.000729	0.00148	CcSEcCtD
Duloxetine—Arthralgia—Ezetimibe—atherosclerosis	0.000729	0.00148	CcSEcCtD
Duloxetine—Chest pain—Ezetimibe—atherosclerosis	0.000729	0.00148	CcSEcCtD
Duloxetine—Nervousness—Niacin—atherosclerosis	0.000728	0.00148	CcSEcCtD
Duloxetine—Flatulence—Pravastatin—atherosclerosis	0.000727	0.00147	CcSEcCtD
Duloxetine—Dry mouth—Lovastatin—atherosclerosis	0.000727	0.00147	CcSEcCtD
Duloxetine—Tension—Pravastatin—atherosclerosis	0.000724	0.00147	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000724	0.00147	CcSEcCtD
Duloxetine—Dysgeusia—Pravastatin—atherosclerosis	0.000723	0.00146	CcSEcCtD
Duloxetine—Muscle spasms—Niacin—atherosclerosis	0.000721	0.00146	CcSEcCtD
Duloxetine—Discomfort—Ezetimibe—atherosclerosis	0.00072	0.00146	CcSEcCtD
Duloxetine—Pain—Rosuvastatin—atherosclerosis	0.000719	0.00146	CcSEcCtD
Duloxetine—Constipation—Rosuvastatin—atherosclerosis	0.000719	0.00146	CcSEcCtD
Duloxetine—Confusional state—Lovastatin—atherosclerosis	0.000718	0.00146	CcSEcCtD
Duloxetine—Nervousness—Pravastatin—atherosclerosis	0.000717	0.00145	CcSEcCtD
Duloxetine—Dry mouth—Ezetimibe—atherosclerosis	0.000713	0.00144	CcSEcCtD
Duloxetine—Anaphylactic shock—Lovastatin—atherosclerosis	0.000712	0.00144	CcSEcCtD
Duloxetine—Muscle spasms—Pravastatin—atherosclerosis	0.00071	0.00144	CcSEcCtD
Duloxetine—Infection—Lovastatin—atherosclerosis	0.000708	0.00143	CcSEcCtD
Duloxetine—Vision blurred—Niacin—atherosclerosis	0.000706	0.00143	CcSEcCtD
Duloxetine—Confusional state—Ezetimibe—atherosclerosis	0.000704	0.00143	CcSEcCtD
Duloxetine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000699	0.00142	CcSEcCtD
Duloxetine—Thrombocytopenia—Lovastatin—atherosclerosis	0.000697	0.00141	CcSEcCtD
Duloxetine—Vision blurred—Pravastatin—atherosclerosis	0.000696	0.00141	CcSEcCtD
Duloxetine—Arthralgia—Simvastatin—atherosclerosis	0.000695	0.00141	CcSEcCtD
Duloxetine—Myalgia—Simvastatin—atherosclerosis	0.000695	0.00141	CcSEcCtD
Duloxetine—Chest pain—Simvastatin—atherosclerosis	0.000695	0.00141	CcSEcCtD
Duloxetine—Infection—Ezetimibe—atherosclerosis	0.000694	0.00141	CcSEcCtD
Duloxetine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000693	0.0014	CcSEcCtD
Duloxetine—Anxiety—Simvastatin—atherosclerosis	0.000693	0.0014	CcSEcCtD
Duloxetine—Tremor—Pravastatin—atherosclerosis	0.000692	0.0014	CcSEcCtD
Duloxetine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000687	0.00139	CcSEcCtD
Duloxetine—Discomfort—Simvastatin—atherosclerosis	0.000687	0.00139	CcSEcCtD
Duloxetine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000685	0.00139	CcSEcCtD
Duloxetine—Angioedema—Niacin—atherosclerosis	0.000685	0.00139	CcSEcCtD
Duloxetine—Ill-defined disorder—Pravastatin—atherosclerosis	0.000685	0.00139	CcSEcCtD
Duloxetine—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000684	0.00139	CcSEcCtD
Duloxetine—Anaemia—Pravastatin—atherosclerosis	0.000682	0.00138	CcSEcCtD
Duloxetine—Anorexia—Lovastatin—atherosclerosis	0.000679	0.00138	CcSEcCtD
Duloxetine—Skin disorder—Ezetimibe—atherosclerosis	0.000679	0.00137	CcSEcCtD
Duloxetine—Angioedema—Pravastatin—atherosclerosis	0.000674	0.00137	CcSEcCtD
Duloxetine—Vertigo—Niacin—atherosclerosis	0.000673	0.00136	CcSEcCtD
Duloxetine—Syncope—Niacin—atherosclerosis	0.000672	0.00136	CcSEcCtD
Duloxetine—Confusional state—Simvastatin—atherosclerosis	0.000672	0.00136	CcSEcCtD
Duloxetine—Leukopenia—Niacin—atherosclerosis	0.000671	0.00136	CcSEcCtD
Duloxetine—Urticaria—Rosuvastatin—atherosclerosis	0.000668	0.00135	CcSEcCtD
Duloxetine—Anaphylactic shock—Simvastatin—atherosclerosis	0.000666	0.00135	CcSEcCtD
Duloxetine—Oedema—Simvastatin—atherosclerosis	0.000666	0.00135	CcSEcCtD
Duloxetine—Malaise—Pravastatin—atherosclerosis	0.000666	0.00135	CcSEcCtD
Duloxetine—Abdominal pain—Rosuvastatin—atherosclerosis	0.000664	0.00135	CcSEcCtD
Duloxetine—Vertigo—Pravastatin—atherosclerosis	0.000663	0.00134	CcSEcCtD
Duloxetine—Palpitations—Niacin—atherosclerosis	0.000662	0.00134	CcSEcCtD
Duloxetine—Infection—Simvastatin—atherosclerosis	0.000662	0.00134	CcSEcCtD
Duloxetine—Leukopenia—Pravastatin—atherosclerosis	0.000661	0.00134	CcSEcCtD
Duloxetine—Loss of consciousness—Niacin—atherosclerosis	0.000659	0.00133	CcSEcCtD
Duloxetine—Cough—Niacin—atherosclerosis	0.000654	0.00133	CcSEcCtD
Duloxetine—Thrombocytopenia—Simvastatin—atherosclerosis	0.000652	0.00132	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000649	0.00131	CcSEcCtD
Duloxetine—Insomnia—Lovastatin—atherosclerosis	0.000644	0.00131	CcSEcCtD
Duloxetine—Cough—Pravastatin—atherosclerosis	0.000644	0.0013	CcSEcCtD
Duloxetine—Paraesthesia—Lovastatin—atherosclerosis	0.00064	0.0013	CcSEcCtD
Duloxetine—Arthralgia—Niacin—atherosclerosis	0.000638	0.00129	CcSEcCtD
Duloxetine—Myalgia—Niacin—atherosclerosis	0.000638	0.00129	CcSEcCtD
Duloxetine—Hypertension—Pravastatin—atherosclerosis	0.000637	0.00129	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000637	0.00129	CcSEcCtD
Duloxetine—Anorexia—Simvastatin—atherosclerosis	0.000635	0.00129	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000634	0.00128	CcSEcCtD
Duloxetine—Insomnia—Ezetimibe—atherosclerosis	0.000632	0.00128	CcSEcCtD
Duloxetine—Myalgia—Pravastatin—atherosclerosis	0.000628	0.00127	CcSEcCtD
Duloxetine—Chest pain—Pravastatin—atherosclerosis	0.000628	0.00127	CcSEcCtD
Duloxetine—Arthralgia—Pravastatin—atherosclerosis	0.000628	0.00127	CcSEcCtD
Duloxetine—Paraesthesia—Ezetimibe—atherosclerosis	0.000627	0.00127	CcSEcCtD
Duloxetine—Dyspepsia—Lovastatin—atherosclerosis	0.000627	0.00127	CcSEcCtD
Duloxetine—Anxiety—Pravastatin—atherosclerosis	0.000626	0.00127	CcSEcCtD
Duloxetine—Dry mouth—Niacin—atherosclerosis	0.000624	0.00126	CcSEcCtD
Duloxetine—Discomfort—Pravastatin—atherosclerosis	0.000621	0.00126	CcSEcCtD
Duloxetine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000619	0.00125	CcSEcCtD
Duloxetine—Decreased appetite—Lovastatin—atherosclerosis	0.000619	0.00125	CcSEcCtD
Duloxetine—Dyspepsia—Ezetimibe—atherosclerosis	0.000615	0.00125	CcSEcCtD
Duloxetine—Fatigue—Lovastatin—atherosclerosis	0.000614	0.00124	CcSEcCtD
Duloxetine—Anaphylactic shock—Niacin—atherosclerosis	0.000612	0.00124	CcSEcCtD
Duloxetine—Oedema—Niacin—atherosclerosis	0.000612	0.00124	CcSEcCtD
Duloxetine—Constipation—Lovastatin—atherosclerosis	0.000609	0.00123	CcSEcCtD
Duloxetine—Pain—Lovastatin—atherosclerosis	0.000609	0.00123	CcSEcCtD
Duloxetine—Confusional state—Pravastatin—atherosclerosis	0.000607	0.00123	CcSEcCtD
Duloxetine—Decreased appetite—Ezetimibe—atherosclerosis	0.000607	0.00123	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000607	0.00123	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000603	0.00122	CcSEcCtD
Duloxetine—Asthenia—Rosuvastatin—atherosclerosis	0.000603	0.00122	CcSEcCtD
Duloxetine—Insomnia—Simvastatin—atherosclerosis	0.000603	0.00122	CcSEcCtD
Duloxetine—Oedema—Pravastatin—atherosclerosis	0.000602	0.00122	CcSEcCtD
Duloxetine—Anaphylactic shock—Pravastatin—atherosclerosis	0.000602	0.00122	CcSEcCtD
Duloxetine—Fatigue—Ezetimibe—atherosclerosis	0.000602	0.00122	CcSEcCtD
Duloxetine—Shock—Niacin—atherosclerosis	0.000602	0.00122	CcSEcCtD
Duloxetine—Infection—Pravastatin—atherosclerosis	0.000598	0.00121	CcSEcCtD
Duloxetine—Paraesthesia—Simvastatin—atherosclerosis	0.000598	0.00121	CcSEcCtD
Duloxetine—Constipation—Ezetimibe—atherosclerosis	0.000597	0.00121	CcSEcCtD
Duloxetine—Pain—Ezetimibe—atherosclerosis	0.000597	0.00121	CcSEcCtD
Duloxetine—Tachycardia—Niacin—atherosclerosis	0.000597	0.00121	CcSEcCtD
Duloxetine—Pruritus—Rosuvastatin—atherosclerosis	0.000595	0.0012	CcSEcCtD
Duloxetine—Skin disorder—Niacin—atherosclerosis	0.000594	0.0012	CcSEcCtD
Duloxetine—Hyperhidrosis—Niacin—atherosclerosis	0.000591	0.0012	CcSEcCtD
Duloxetine—Thrombocytopenia—Pravastatin—atherosclerosis	0.00059	0.00119	CcSEcCtD
Duloxetine—Feeling abnormal—Lovastatin—atherosclerosis	0.000587	0.00119	CcSEcCtD
Duloxetine—Dyspepsia—Simvastatin—atherosclerosis	0.000586	0.00119	CcSEcCtD
Duloxetine—Anorexia—Niacin—atherosclerosis	0.000583	0.00118	CcSEcCtD
Duloxetine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000582	0.00118	CcSEcCtD
Duloxetine—Hyperhidrosis—Pravastatin—atherosclerosis	0.000582	0.00118	CcSEcCtD
Duloxetine—Decreased appetite—Simvastatin—atherosclerosis	0.000579	0.00117	CcSEcCtD
Duloxetine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000576	0.00117	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000575	0.00117	CcSEcCtD
Duloxetine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000575	0.00117	CcSEcCtD
Duloxetine—Fatigue—Simvastatin—atherosclerosis	0.000574	0.00116	CcSEcCtD
Duloxetine—Anorexia—Pravastatin—atherosclerosis	0.000574	0.00116	CcSEcCtD
Duloxetine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000571	0.00116	CcSEcCtD
Duloxetine—Pain—Simvastatin—atherosclerosis	0.00057	0.00115	CcSEcCtD
Duloxetine—Constipation—Simvastatin—atherosclerosis	0.00057	0.00115	CcSEcCtD
Duloxetine—Urticaria—Lovastatin—atherosclerosis	0.000566	0.00115	CcSEcCtD
Duloxetine—Abdominal pain—Lovastatin—atherosclerosis	0.000563	0.00114	CcSEcCtD
Duloxetine—Body temperature increased—Lovastatin—atherosclerosis	0.000563	0.00114	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000557	0.00113	CcSEcCtD
Duloxetine—Dizziness—Rosuvastatin—atherosclerosis	0.000556	0.00113	CcSEcCtD
Duloxetine—Urticaria—Ezetimibe—atherosclerosis	0.000555	0.00112	CcSEcCtD
Duloxetine—Insomnia—Niacin—atherosclerosis	0.000553	0.00112	CcSEcCtD
Duloxetine—Abdominal pain—Ezetimibe—atherosclerosis	0.000552	0.00112	CcSEcCtD
Duloxetine—Body temperature increased—Ezetimibe—atherosclerosis	0.000552	0.00112	CcSEcCtD
Duloxetine—Paraesthesia—Niacin—atherosclerosis	0.000549	0.00111	CcSEcCtD
Duloxetine—Feeling abnormal—Simvastatin—atherosclerosis	0.000549	0.00111	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000549	0.00111	CcSEcCtD
Duloxetine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000545	0.0011	CcSEcCtD
Duloxetine—Insomnia—Pravastatin—atherosclerosis	0.000545	0.0011	CcSEcCtD
Duloxetine—Somnolence—Niacin—atherosclerosis	0.000544	0.0011	CcSEcCtD
Duloxetine—Paraesthesia—Pravastatin—atherosclerosis	0.000541	0.0011	CcSEcCtD
Duloxetine—Dyspepsia—Niacin—atherosclerosis	0.000539	0.00109	CcSEcCtD
Duloxetine—Decreased appetite—Niacin—atherosclerosis	0.000532	0.00108	CcSEcCtD
Duloxetine—Dyspepsia—Pravastatin—atherosclerosis	0.00053	0.00107	CcSEcCtD
Duloxetine—Rash—Rosuvastatin—atherosclerosis	0.00053	0.00107	CcSEcCtD
Duloxetine—Dermatitis—Rosuvastatin—atherosclerosis	0.000529	0.00107	CcSEcCtD
Duloxetine—Urticaria—Simvastatin—atherosclerosis	0.000529	0.00107	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000528	0.00107	CcSEcCtD
Duloxetine—Abdominal pain—Simvastatin—atherosclerosis	0.000527	0.00107	CcSEcCtD
Duloxetine—Body temperature increased—Simvastatin—atherosclerosis	0.000527	0.00107	CcSEcCtD
Duloxetine—Headache—Rosuvastatin—atherosclerosis	0.000527	0.00107	CcSEcCtD
Duloxetine—Hypersensitivity—Lovastatin—atherosclerosis	0.000525	0.00106	CcSEcCtD
Duloxetine—Decreased appetite—Pravastatin—atherosclerosis	0.000524	0.00106	CcSEcCtD
Duloxetine—Pain—Niacin—atherosclerosis	0.000523	0.00106	CcSEcCtD
Duloxetine—Fatigue—Pravastatin—atherosclerosis	0.000519	0.00105	CcSEcCtD
Duloxetine—Constipation—Pravastatin—atherosclerosis	0.000515	0.00104	CcSEcCtD
Duloxetine—Pain—Pravastatin—atherosclerosis	0.000515	0.00104	CcSEcCtD
Duloxetine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000515	0.00104	CcSEcCtD
Duloxetine—Asthenia—Lovastatin—atherosclerosis	0.000511	0.00104	CcSEcCtD
Duloxetine—Pruritus—Lovastatin—atherosclerosis	0.000504	0.00102	CcSEcCtD
Duloxetine—Fluoxetine—ALB—atherosclerosis	0.000503	0.0402	CrCbGaD
Duloxetine—Asthenia—Ezetimibe—atherosclerosis	0.000501	0.00102	CcSEcCtD
Duloxetine—Gastrointestinal pain—Niacin—atherosclerosis	0.0005	0.00101	CcSEcCtD
Duloxetine—Nausea—Rosuvastatin—atherosclerosis	0.000499	0.00101	CcSEcCtD
Duloxetine—Feeling abnormal—Pravastatin—atherosclerosis	0.000496	0.00101	CcSEcCtD
Duloxetine—Pruritus—Ezetimibe—atherosclerosis	0.000494	0.001	CcSEcCtD
Duloxetine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000493	0.000998	CcSEcCtD
Duloxetine—Hypersensitivity—Simvastatin—atherosclerosis	0.000491	0.000995	CcSEcCtD
Duloxetine—Diarrhoea—Lovastatin—atherosclerosis	0.000487	0.000987	CcSEcCtD
Duloxetine—Urticaria—Niacin—atherosclerosis	0.000486	0.000985	CcSEcCtD
Duloxetine—Abdominal pain—Niacin—atherosclerosis	0.000484	0.00098	CcSEcCtD
Duloxetine—Body temperature increased—Niacin—atherosclerosis	0.000484	0.00098	CcSEcCtD
Duloxetine—Urticaria—Pravastatin—atherosclerosis	0.000479	0.00097	CcSEcCtD
Duloxetine—Asthenia—Simvastatin—atherosclerosis	0.000478	0.000969	CcSEcCtD
Duloxetine—Diarrhoea—Ezetimibe—atherosclerosis	0.000478	0.000968	CcSEcCtD
Duloxetine—Abdominal pain—Pravastatin—atherosclerosis	0.000476	0.000965	CcSEcCtD
Duloxetine—Body temperature increased—Pravastatin—atherosclerosis	0.000476	0.000965	CcSEcCtD
Duloxetine—Pruritus—Simvastatin—atherosclerosis	0.000471	0.000955	CcSEcCtD
Duloxetine—Dizziness—Lovastatin—atherosclerosis	0.000471	0.000954	CcSEcCtD
Duloxetine—Dizziness—Ezetimibe—atherosclerosis	0.000462	0.000936	CcSEcCtD
Duloxetine—Diarrhoea—Simvastatin—atherosclerosis	0.000456	0.000924	CcSEcCtD
Duloxetine—Vomiting—Lovastatin—atherosclerosis	0.000453	0.000918	CcSEcCtD
Duloxetine—Hypersensitivity—Niacin—atherosclerosis	0.000451	0.000913	CcSEcCtD
Duloxetine—Rash—Lovastatin—atherosclerosis	0.000449	0.00091	CcSEcCtD
Duloxetine—Dermatitis—Lovastatin—atherosclerosis	0.000449	0.000909	CcSEcCtD
Duloxetine—Headache—Lovastatin—atherosclerosis	0.000446	0.000904	CcSEcCtD
Duloxetine—Vomiting—Ezetimibe—atherosclerosis	0.000444	0.0009	CcSEcCtD
Duloxetine—Hypersensitivity—Pravastatin—atherosclerosis	0.000444	0.000899	CcSEcCtD
Duloxetine—Dizziness—Simvastatin—atherosclerosis	0.000441	0.000893	CcSEcCtD
Duloxetine—Rash—Ezetimibe—atherosclerosis	0.000441	0.000892	CcSEcCtD
Duloxetine—Dermatitis—Ezetimibe—atherosclerosis	0.00044	0.000892	CcSEcCtD
Duloxetine—Asthenia—Niacin—atherosclerosis	0.000439	0.000889	CcSEcCtD
Duloxetine—Headache—Ezetimibe—atherosclerosis	0.000438	0.000887	CcSEcCtD
Duloxetine—Pruritus—Niacin—atherosclerosis	0.000433	0.000877	CcSEcCtD
Duloxetine—Asthenia—Pravastatin—atherosclerosis	0.000432	0.000876	CcSEcCtD
Duloxetine—Pruritus—Pravastatin—atherosclerosis	0.000426	0.000863	CcSEcCtD
Duloxetine—Vomiting—Simvastatin—atherosclerosis	0.000424	0.000858	CcSEcCtD
Duloxetine—Nausea—Lovastatin—atherosclerosis	0.000423	0.000857	CcSEcCtD
Duloxetine—Rash—Simvastatin—atherosclerosis	0.00042	0.000851	CcSEcCtD
Duloxetine—Dermatitis—Simvastatin—atherosclerosis	0.00042	0.00085	CcSEcCtD
Duloxetine—Diarrhoea—Niacin—atherosclerosis	0.000419	0.000848	CcSEcCtD
Duloxetine—Headache—Simvastatin—atherosclerosis	0.000417	0.000846	CcSEcCtD
Duloxetine—Nausea—Ezetimibe—atherosclerosis	0.000415	0.000841	CcSEcCtD
Duloxetine—Diarrhoea—Pravastatin—atherosclerosis	0.000412	0.000835	CcSEcCtD
Duloxetine—Dizziness—Niacin—atherosclerosis	0.000405	0.00082	CcSEcCtD
Duloxetine—HTR2A—connective tissue—atherosclerosis	0.000401	0.0246	CbGeAlD
Duloxetine—Dizziness—Pravastatin—atherosclerosis	0.000398	0.000807	CcSEcCtD
Duloxetine—Nausea—Simvastatin—atherosclerosis	0.000396	0.000802	CcSEcCtD
Duloxetine—Vomiting—Niacin—atherosclerosis	0.000389	0.000788	CcSEcCtD
Duloxetine—Rash—Niacin—atherosclerosis	0.000386	0.000782	CcSEcCtD
Duloxetine—Dermatitis—Niacin—atherosclerosis	0.000385	0.000781	CcSEcCtD
Duloxetine—Headache—Niacin—atherosclerosis	0.000383	0.000776	CcSEcCtD
Duloxetine—Vomiting—Pravastatin—atherosclerosis	0.000383	0.000776	CcSEcCtD
Duloxetine—Rash—Pravastatin—atherosclerosis	0.00038	0.000769	CcSEcCtD
Duloxetine—Dermatitis—Pravastatin—atherosclerosis	0.000379	0.000769	CcSEcCtD
Duloxetine—Headache—Pravastatin—atherosclerosis	0.000377	0.000765	CcSEcCtD
Duloxetine—Nausea—Niacin—atherosclerosis	0.000363	0.000736	CcSEcCtD
Duloxetine—Nausea—Pravastatin—atherosclerosis	0.000358	0.000725	CcSEcCtD
Duloxetine—HTR2A—cardiovascular system—atherosclerosis	0.000349	0.0214	CbGeAlD
Duloxetine—CYP1A2—liver—atherosclerosis	0.000276	0.0169	CbGeAlD
Duloxetine—HTR2A—liver—atherosclerosis	0.000216	0.0133	CbGeAlD
Duloxetine—CYP2D6—liver—atherosclerosis	0.000197	0.0121	CbGeAlD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—atherosclerosis	4.2e-05	0.000208	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—F2—atherosclerosis	4.15e-05	0.000205	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP3—atherosclerosis	4.14e-05	0.000205	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF2—atherosclerosis	4.12e-05	0.000204	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AGT—atherosclerosis	4.08e-05	0.000201	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR2—atherosclerosis	4.02e-05	0.000199	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EDNRA—atherosclerosis	4.02e-05	0.000199	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PRKCG—atherosclerosis	4.02e-05	0.000199	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CYBA—atherosclerosis	4.01e-05	0.000198	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VWF—atherosclerosis	4e-05	0.000198	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOB—atherosclerosis	4e-05	0.000198	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCG1—atherosclerosis	4e-05	0.000197	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOC3—atherosclerosis	3.98e-05	0.000197	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CG—atherosclerosis	3.97e-05	0.000196	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL8—atherosclerosis	3.97e-05	0.000196	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LDLR—atherosclerosis	3.96e-05	0.000195	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP27A1—atherosclerosis	3.95e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EDN1—atherosclerosis	3.94e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—GHRL—atherosclerosis	3.92e-05	0.000194	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PLAT—atherosclerosis	3.92e-05	0.000194	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PARP1—atherosclerosis	3.92e-05	0.000194	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL5—atherosclerosis	3.91e-05	0.000193	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AGT—atherosclerosis	3.9e-05	0.000193	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL3—atherosclerosis	3.86e-05	0.000191	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LPL—atherosclerosis	3.82e-05	0.000189	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—F2—atherosclerosis	3.77e-05	0.000186	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—FABP4—atherosclerosis	3.76e-05	0.000186	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LCAT—atherosclerosis	3.76e-05	0.000186	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOA2—atherosclerosis	3.75e-05	0.000185	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PLA2G2A—atherosclerosis	3.75e-05	0.000185	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALOX15—atherosclerosis	3.75e-05	0.000185	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALOX5AP—atherosclerosis	3.75e-05	0.000185	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PRKCG—atherosclerosis	3.72e-05	0.000184	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCG5—atherosclerosis	3.7e-05	0.000183	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NCF1—atherosclerosis	3.7e-05	0.000183	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOA4—atherosclerosis	3.69e-05	0.000182	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP7A1—atherosclerosis	3.62e-05	0.000179	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SPP1—atherosclerosis	3.62e-05	0.000179	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CG—atherosclerosis	3.6e-05	0.000178	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL8—atherosclerosis	3.6e-05	0.000178	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—F2—atherosclerosis	3.6e-05	0.000178	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LPA—atherosclerosis	3.57e-05	0.000177	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AGT—atherosclerosis	3.54e-05	0.000175	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR2—atherosclerosis	3.49e-05	0.000173	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EDNRA—atherosclerosis	3.49e-05	0.000173	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CYBA—atherosclerosis	3.48e-05	0.000172	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—BGN—atherosclerosis	3.46e-05	0.000171	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOB—atherosclerosis	3.45e-05	0.000171	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CG—atherosclerosis	3.45e-05	0.00017	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KNG1—atherosclerosis	3.44e-05	0.00017	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOA5—atherosclerosis	3.43e-05	0.000169	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGTR1—atherosclerosis	3.42e-05	0.000169	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PLAT—atherosclerosis	3.41e-05	0.000168	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—GHRL—atherosclerosis	3.41e-05	0.000168	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PARP1—atherosclerosis	3.41e-05	0.000168	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL2—atherosclerosis	3.36e-05	0.000166	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PDGFB—atherosclerosis	3.35e-05	0.000165	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP27A1—atherosclerosis	3.35e-05	0.000165	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PLG—atherosclerosis	3.33e-05	0.000165	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	3.3e-05	0.000163	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	3.3e-05	0.000163	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—F2—atherosclerosis	3.27e-05	0.000162	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AGT—atherosclerosis	3.27e-05	0.000162	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—atherosclerosis	3.24e-05	0.00016	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	3.22e-05	0.000159	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOE—atherosclerosis	3.2e-05	0.000158	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—LEP—atherosclerosis	3.2e-05	0.000158	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALOX5—atherosclerosis	3.19e-05	0.000157	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CAV1—atherosclerosis	3.17e-05	0.000157	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALOX15—atherosclerosis	3.17e-05	0.000157	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOA2—atherosclerosis	3.17e-05	0.000157	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLA2G2A—atherosclerosis	3.17e-05	0.000157	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALOX5AP—atherosclerosis	3.17e-05	0.000157	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APOA1—atherosclerosis	3.17e-05	0.000156	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SOCS3—atherosclerosis	3.16e-05	0.000156	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCG5—atherosclerosis	3.14e-05	0.000155	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	3.13e-05	0.000155	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CG—atherosclerosis	3.13e-05	0.000155	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ESR1—atherosclerosis	3.06e-05	0.000151	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP3—atherosclerosis	3.05e-05	0.000151	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF2—atherosclerosis	3.04e-05	0.00015	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LPA—atherosclerosis	3.03e-05	0.00015	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—F2—atherosclerosis	3.02e-05	0.000149	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT1—atherosclerosis	2.99e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KNG1—atherosclerosis	2.99e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGTR1—atherosclerosis	2.97e-05	0.000147	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOB—atherosclerosis	2.95e-05	0.000146	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—BGN—atherosclerosis	2.93e-05	0.000145	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL8—atherosclerosis	2.92e-05	0.000144	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL2—atherosclerosis	2.91e-05	0.000144	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	2.91e-05	0.000144	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOA5—atherosclerosis	2.9e-05	0.000143	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EDN1—atherosclerosis	2.9e-05	0.000143	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PLG—atherosclerosis	2.9e-05	0.000143	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CG—atherosclerosis	2.89e-05	0.000143	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL5—atherosclerosis	2.88e-05	0.000142	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NAMPT—atherosclerosis	2.86e-05	0.000141	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LIPC—atherosclerosis	2.84e-05	0.00014	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOC3—atherosclerosis	2.82e-05	0.000139	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	2.82e-05	0.000139	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LPL—atherosclerosis	2.81e-05	0.000139	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LDLR—atherosclerosis	2.8e-05	0.000139	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	2.79e-05	0.000138	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK3—atherosclerosis	2.77e-05	0.000137	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	2.76e-05	0.000137	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SOCS3—atherosclerosis	2.74e-05	0.000135	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CETP—atherosclerosis	2.74e-05	0.000135	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	2.74e-05	0.000135	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—INS—atherosclerosis	2.74e-05	0.000135	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRKCG—atherosclerosis	2.74e-05	0.000135	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	2.73e-05	0.000135	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALOX5—atherosclerosis	2.7e-05	0.000133	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL2—atherosclerosis	2.69e-05	0.000133	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SPP1—atherosclerosis	2.67e-05	0.000132	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—atherosclerosis	2.65e-05	0.000131	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP3—atherosclerosis	2.65e-05	0.000131	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1—atherosclerosis	2.65e-05	0.000131	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF2—atherosclerosis	2.64e-05	0.00013	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SCARB1—atherosclerosis	2.62e-05	0.00013	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOB—atherosclerosis	2.56e-05	0.000126	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—atherosclerosis	2.54e-05	0.000125	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EDN1—atherosclerosis	2.52e-05	0.000124	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SERPINE1—atherosclerosis	2.51e-05	0.000124	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL5—atherosclerosis	2.5e-05	0.000123	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	2.49e-05	0.000123	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMGCR—atherosclerosis	2.48e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PDGFB—atherosclerosis	2.47e-05	0.000122	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LPL—atherosclerosis	2.44e-05	0.000121	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NAMPT—atherosclerosis	2.42e-05	0.00012	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AGT—atherosclerosis	2.41e-05	0.000119	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	2.41e-05	0.000119	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LIPC—atherosclerosis	2.41e-05	0.000119	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOS3—atherosclerosis	2.4e-05	0.000119	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOC3—atherosclerosis	2.39e-05	0.000118	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKCG—atherosclerosis	2.38e-05	0.000117	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LDLR—atherosclerosis	2.38e-05	0.000117	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOE—atherosclerosis	2.36e-05	0.000117	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—LEP—atherosclerosis	2.36e-05	0.000117	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CAV1—atherosclerosis	2.34e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APOA1—atherosclerosis	2.33e-05	0.000115	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CETP—atherosclerosis	2.32e-05	0.000115	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SPP1—atherosclerosis	2.31e-05	0.000114	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—atherosclerosis	2.3e-05	0.000114	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ESR1—atherosclerosis	2.25e-05	0.000111	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—F2—atherosclerosis	2.22e-05	0.00011	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SCARB1—atherosclerosis	2.22e-05	0.00011	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCA1—atherosclerosis	2.21e-05	0.000109	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	2.16e-05	0.000107	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDGFB—atherosclerosis	2.14e-05	0.000106	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CG—atherosclerosis	2.13e-05	0.000105	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—atherosclerosis	2.13e-05	0.000105	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMGCR—atherosclerosis	2.1e-05	0.000104	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AGT—atherosclerosis	2.09e-05	0.000103	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—atherosclerosis	2.06e-05	0.000102	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOE—atherosclerosis	2.05e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—LEP—atherosclerosis	2.05e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK3—atherosclerosis	2.04e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CAV1—atherosclerosis	2.03e-05	0.0001	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APOA1—atherosclerosis	2.03e-05	0.0001	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—atherosclerosis	2.02e-05	0.0001	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—INS—atherosclerosis	2.02e-05	9.96e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL2—atherosclerosis	1.98e-05	9.8e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ESR1—atherosclerosis	1.96e-05	9.66e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—atherosclerosis	1.95e-05	9.63e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—F2—atherosclerosis	1.93e-05	9.54e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—atherosclerosis	1.93e-05	9.51e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NFKB1—atherosclerosis	1.91e-05	9.41e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—HMOX1—atherosclerosis	1.89e-05	9.36e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.89e-05	9.35e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK8—atherosclerosis	1.87e-05	9.25e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCA1—atherosclerosis	1.87e-05	9.24e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—atherosclerosis	1.87e-05	9.23e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	1.85e-05	9.15e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	1.85e-05	9.13e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOB—atherosclerosis	1.81e-05	8.97e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	1.77e-05	8.75e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOS3—atherosclerosis	1.77e-05	8.73e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.77e-05	8.72e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—INS—atherosclerosis	1.75e-05	8.65e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—LPL—atherosclerosis	1.73e-05	8.56e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—atherosclerosis	1.73e-05	8.54e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL2—atherosclerosis	1.72e-05	8.51e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—atherosclerosis	1.71e-05	8.46e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—atherosclerosis	1.69e-05	8.36e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GPX1—atherosclerosis	1.69e-05	8.35e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CD36—atherosclerosis	1.65e-05	8.13e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK3—atherosclerosis	1.64e-05	8.08e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	1.61e-05	7.94e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—HMOX1—atherosclerosis	1.6e-05	7.93e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—atherosclerosis	1.59e-05	7.84e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	1.57e-05	7.75e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.56e-05	7.71e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOB—atherosclerosis	1.54e-05	7.6e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOS3—atherosclerosis	1.53e-05	7.58e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARA—atherosclerosis	1.53e-05	7.56e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	1.51e-05	7.48e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTM1—atherosclerosis	1.5e-05	7.39e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—atherosclerosis	1.49e-05	7.37e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AGT—atherosclerosis	1.48e-05	7.32e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—LPL—atherosclerosis	1.47e-05	7.25e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOE—atherosclerosis	1.45e-05	7.18e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAV1—atherosclerosis	1.44e-05	7.11e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—APOA1—atherosclerosis	1.44e-05	7.09e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GPX1—atherosclerosis	1.43e-05	7.08e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—atherosclerosis	1.42e-05	7.01e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	1.4e-05	6.93e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CD36—atherosclerosis	1.39e-05	6.89e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	1.38e-05	6.81e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	1.38e-05	6.79e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	1.36e-05	6.73e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—MTHFR—atherosclerosis	1.32e-05	6.53e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	1.32e-05	6.5e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.31e-05	6.48e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARA—atherosclerosis	1.3e-05	6.41e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—atherosclerosis	1.29e-05	6.4e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	1.27e-05	6.29e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—atherosclerosis	1.27e-05	6.25e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—atherosclerosis	1.26e-05	6.23e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AGT—atherosclerosis	1.26e-05	6.2e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—INS—atherosclerosis	1.24e-05	6.13e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—atherosclerosis	1.23e-05	6.08e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOE—atherosclerosis	1.23e-05	6.08e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAV1—atherosclerosis	1.22e-05	6.02e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	1.22e-05	6.02e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—APOA1—atherosclerosis	1.22e-05	6.01e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	1.2e-05	5.95e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	1.2e-05	5.92e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—atherosclerosis	1.2e-05	5.91e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	1.19e-05	5.9e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	1.17e-05	5.77e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—atherosclerosis	1.14e-05	5.62e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CG—atherosclerosis	1.11e-05	5.49e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	1.11e-05	5.46e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—atherosclerosis	1.1e-05	5.45e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—atherosclerosis	1.09e-05	5.41e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NOS3—atherosclerosis	1.09e-05	5.38e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—atherosclerosis	1.07e-05	5.3e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—INS—atherosclerosis	1.05e-05	5.19e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	1.05e-05	5.17e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	1.01e-05	5.01e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—atherosclerosis	9.95e-06	4.92e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—atherosclerosis	9.64e-06	4.76e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NOS3—atherosclerosis	9.22e-06	4.55e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—atherosclerosis	8.81e-06	4.35e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—atherosclerosis	8.43e-06	4.17e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—atherosclerosis	8.12e-06	4.01e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—atherosclerosis	7.65e-06	3.78e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—atherosclerosis	7.05e-06	3.49e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—atherosclerosis	5e-06	2.47e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—atherosclerosis	4.24e-06	2.09e-05	CbGpPWpGaD
